Vertex and Concert Pharmaceuticals complete asset purchase agreement for CTP-656
Vertex and Concert Pharmaceuticals announced the completion of their asset purchase agreement. Vertex now has worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. July 25, 2017